慢性斑块状银屑病患者体重对生物治疗反应的影响。
The influence of body weight of patients with chronic plaque psoriasis on biological treatment response.
作者信息
Kisielnicka Anna, Szczerkowska-Dobosz Aneta, Nowicki Roman J
机构信息
Student Dermatological Society of Medical University of Gdansk, Gdansk, Poland.
Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland.
出版信息
Postepy Dermatol Alergol. 2020 Apr;37(2):168-173. doi: 10.5114/ada.2020.94835. Epub 2020 May 5.
Abstract
Psoriasis is a chronic inflammatory disease of the skin. The new era of biological therapies initiated a shift in the definition of the disease therapeutic success, however, recent reports in the literature draw attention to the treatment-induced weight gain in psoriatic patients. Therefore, it is worth considering the body mass index influence on the biological treatment of chronic plaque psoriasis, seeing that it has manifold associations with the disease and may play an important role in clinical practice management.
摘要
银屑病是一种慢性皮肤炎症性疾病。生物疗法的新时代引发了疾病治疗成功定义的转变，然而，文献中的最新报道提请注意银屑病患者治疗引起的体重增加。因此，鉴于体重指数与该疾病有多种关联且可能在临床实践管理中发挥重要作用，值得考虑其对慢性斑块状银屑病生物治疗的影响。
相似文献
1
The influence of body weight of patients with chronic plaque psoriasis on biological treatment response.慢性斑块状银屑病患者体重对生物治疗反应的影响。
Postepy Dermatol Alergol. 2020 Apr;37(2):168-173. doi: 10.5114/ada.2020.94835. Epub 2020 May 5.
2
Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.抗肿瘤坏死因子-α治疗可增加慢性斑块状银屑病患者的体重：一项回顾性队列研究。
J Eur Acad Dermatol Venereol. 2008 Mar;22(3):341-4. doi: 10.1111/j.1468-3083.2007.02429.x. Epub 2007 Nov 14.
3
Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.银屑病皮肤中的血管生成及其在使用依那西普后的变化：电视毛细血管镜、组织学和免疫组织化学评估。
Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):371-7. doi: 10.1177/039463200902200214.
4
Infliximab in psoriasis and psoriatic arthritis.英夫利昔单抗治疗银屑病和银屑病关节炎。
BioDrugs. 2013 Jan;27 Suppl 1:13-23. doi: 10.1007/BF03325638.
5
Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23.司库奇尤单抗治疗慢性斑块状银屑病和银屑病关节炎患者引发炎症性肠病：一例报告及靶向白细胞介素-23 p19亚基新型生物制剂作用的综述
Case Rep Med. 2020 Jul 24;2020:9404505. doi: 10.1155/2020/9404505. eCollection 2020.
6
Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies.生物疗法治疗斑块状银屑病后体重及临床参数变化的比较
Curr Med Res Opin. 2009 Sep;25(9):2311-6. doi: 10.1185/03007990903162465.
7
Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.乌司奴单抗不会增加慢性斑块型银屑病患者的体重指数：一项前瞻性队列研究。
Br J Dermatol. 2013 May;168(5):1124-7. doi: 10.1111/bjd.12235.
8
Acupuncture as a Complementary Method of Traditional Psoriasis Treatment: Myth or Reality?针灸作为传统银屑病治疗的辅助方法：神话还是现实？
Acta Dermatovenerol Croat. 2016 Aug;24(3):221-2.
9
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.阿达木单抗用于治疗重度银屑病和银屑病关节炎。
Expert Opin Biol Ther. 2008 Mar;8(3):363-70. doi: 10.1517/14712598.8.3.363.
10
Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.依那西普对银屑病及银屑病关节炎患者C反应蛋白水平的影响。
Br J Dermatol. 2008 Aug;159(2):322-30. doi: 10.1111/j.1365-2133.2008.08628.x. Epub 2008 May 22.
引用本文的文献
1
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In-Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO-4 Trial.口服选择性变构酪氨酸激酶2抑制剂氘可来昔替尼治疗日本斑块状银屑病患者：3期POETYK PSO-4试验疗效与安全性的深入分析
J Dermatol. 2025 Jun;52(6):953-966. doi: 10.1111/1346-8138.17744. Epub 2025 Apr 30.
2
Association Between a Body Shape Index and Body Roundness Index with Prevalence of Psoriasis: A Cross-Sectional Population-Based Study.身体形态指数和身体圆润度指数与银屑病患病率之间的关联：一项基于人群的横断面研究。
Clin Cosmet Investig Dermatol. 2025 Mar 18;18:627-638. doi: 10.2147/CCID.S512864. eCollection 2025.
3
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.司库奇尤单抗剂量递增治疗中重度斑块状银屑病患者的疗效和安全性：来自 PURE 登记研究的数据。
Arch Dermatol Res. 2024 Jun 8;316(7):362. doi: 10.1007/s00403-024-03122-w.
4
Transcriptomic meta-analysis characterizes molecular commonalities between psoriasis and obesity.转录组学荟萃分析描绘银屑病和肥胖之间的分子共性。
Genes Immun. 2024 Jun;25(3):179-187. doi: 10.1038/s41435-024-00271-w. Epub 2024 Apr 5.
5
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.德卡伐替尼，一种口服、选择性、变构酪氨酸激酶2抑制剂，用于日本中重度斑块状、红皮病型或泛发性脓疱型银屑病患者：一项开放标签3期试验的疗效和安全性结果。
J Dermatol. 2024 Mar;51(3):365-379. doi: 10.1111/1346-8138.17074. Epub 2024 Jan 24.
6
A population-based projection of psoriatic arthritis in Germany until 2050: analysis of national statutory health insurance data of 65 million German population.一项针对德国直至 2050 年的银屑病关节炎的基于人群的预测：对 6500 万德国人口的国家法定健康保险数据的分析。
Rheumatol Int. 2023 Nov;43(11):2037-2047. doi: 10.1007/s00296-023-05422-2. Epub 2023 Aug 19.
7
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.布罗达单抗治疗中重度银屑病：专家德尔菲共识声明
J Clin Med. 2023 May 18;12(10):3545. doi: 10.3390/jcm12103545.
8
Effect of low-calorie diet on psoriasis severity index, triglycerides, liver enzymes, and quality of life in psoriatic patients with non-alcoholic fatty liver disease.低热量饮食对非酒精性脂肪性肝病银屑病患者的银屑病严重程度指数、甘油三酯、肝酶及生活质量的影响。
Reumatologia. 2023;61(2):116-122. doi: 10.5114/reum/162995. Epub 2023 May 10.
9
Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis.银屑病生物制剂的依从性和持续性：系统评价与荟萃分析
J Clin Med. 2022 Mar 9;11(6):1506. doi: 10.3390/jcm11061506.
10
Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study.司库奇尤单抗治疗中重度斑块状银屑病患者的有效性和安全性——一项真实世界回顾性研究
Postepy Dermatol Alergol. 2021 Dec;38(6):973-978. doi: 10.5114/ada.2020.97066. Epub 2020 Jul 11.
本文引用的文献
1
Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.肿瘤坏死因子-α、白细胞介素-23 和白细胞介素-17A 抑制剂对银屑病患者体重和体重指数的影响。
J Dermatol. 2018 Sep;45(9):1130-1134. doi: 10.1111/1346-8138.14526. Epub 2018 Jul 13.
2
Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3.依奇珠单抗治疗对中重度斑块型银屑病患者的心血管参数无显著影响：UNCOVER-1、UNCOVER-2 和 UNCOVER-3 研究结果。
J Am Acad Dermatol. 2018 Jul;79(1):104-109.e8. doi: 10.1016/j.jaad.2018.02.074. Epub 2018 Mar 13.
3
Psoriasis and cardiovascular disease risk factors: the HUNT Study, Norway.银屑病与心血管病危险因素：挪威亨于尔特研究
J Eur Acad Dermatol Venereol. 2018 May;32(5):776-782. doi: 10.1111/jdv.14835. Epub 2018 Mar 6.
4
Old and New Biological Therapies for Psoriasis.银屑病的新旧生物疗法。
Int J Mol Sci. 2017 Nov 1;18(11):2297. doi: 10.3390/ijms18112297.
5
Changes in Body Mass Index and Lipid Profile in Psoriatic Patients After Treatment With Standard Protocol of Infliximab.接受英夫利昔单抗标准方案治疗后银屑病患者的体重指数和血脂谱变化
Acta Med Iran. 2016 Sep;54(9):570-575.
6
Overweight and Weight Gain Predict Psoriasis Development in a Population-based Cohort.在一项基于人群的队列研究中，超重和体重增加可预测银屑病的发生。
Acta Derm Venereol. 2017 Mar 10;97(3):332-339. doi: 10.2340/00015555-2530.
7
Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort.在日常实践中，接受生物治疗的银屑病患者的高临床应答频率和预测因素：来自前瞻性、多中心 BioCAPTURE 队列的结果。
Br J Dermatol. 2017 Mar;176(3):786-793. doi: 10.1111/bjd.14888. Epub 2016 Oct 7.
8
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study.阿达木单抗治疗银屑病和银屑病关节炎的9年真实世界经验：一项单中心回顾性研究结果
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):304-311. doi: 10.1111/jdv.13771. Epub 2016 Jun 21.
9
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.在日常实践中，接受阿达木单抗、依那西普或乌司奴单抗治疗的银屑病患者，体重指数预测因无效而停药，而女性则预测因副作用而停药：来自 BioCAPTURE 登记处的前瞻性、比较、长期药物生存研究。
Br J Dermatol. 2016 Aug;175(2):340-7. doi: 10.1111/bjd.14552. Epub 2016 Jun 25.
10
Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.银屑病全身治疗的药物安全性：来自德国银屑病登记处PsoBest的结果。
Arch Dermatol Res. 2015 Dec;307(10):875-83. doi: 10.1007/s00403-015-1593-8. Epub 2015 Sep 10.
Zotero 插件